The following discussion should be read in conjunction with the Consolidated Financial Statements and notes thereto contained herein. We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and...
Novartis announces extension to FDA review period for multiple myeloma investigational compound LBH589. Novartis International AG/ Novartis announces extension to FDA review period for multiple myeloma investigational compound LBH589. Basel, November 25, 2014- Novartis announced today that the US Food and Drug Administration has extended their...
Novartis International AG/ Novartis announces extension to FDA review period for multiple myeloma investigational compound LBH589. Basel, November 25, 2014- Novartis announced today that the US Food and Drug Administration has extended their priority review period by up to three months for the new drug application of LBH589 in combination with...
Taglich Brothers, Inc. announces it initiated coverage of Trxade Group, Inc.. Trxade Group Inc., based in Lutz, Florida, operates an Internet-based exchange that promotes and enables trading among independent pharmacies and pharmaceutical suppliers. Proprietary software enables users of Trxade's network to compare prices of branded and generic drug
By a News Reporter-Staff News Editor at Clinical Trials Week Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy, HIV and Multiple Sclerosis, is announcing the recertification of their Plantation, Florida laboratory facilities. "We are happy to report that the sales of Nyloxin have been steadily in
On November 20, 2014, Endo Pharmaceuticals Solutions Inc., Bayer Intellectual Property GmbH and Bayer Pharma AG filed suit against Perrigo in the United States District Court for the District of Delaware, alleging patent infringement. Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This filing highlights our continued investment in br
Dr. Reddy's Laboratories has launched its over-the-counter Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg/ 120 mg, a bioequivalent generic version of Allegra-D? 12 Hour Allergy& Congestion, in the U.S. market on November 18, 2014. Dr. Reddy's Laboratories is an integrated global pharmaceutical compan
*Cosentyx is recommended as first-line systemic therapy for the treatment of moderate-to-severe plaque psoriasis in adult patients in Europe* In Phase III studies, 70% or more patients achieved clear skin or almost clear skin with secukinumab 300 mg during the first 16 weeks of treatment* Clinical trials consistently showed very high skin clearance
The patent is expected to expire in March of 2028. Orexigen expects the patent to be listed in the Orange Book maintained by the United States Food and Drug Administration. "A key component of Orexigen's strategy is to strengthen and extend intellectual property protection for Contrave," said Michael Narachi, CEO of Orexigen. Orexigen has also fil
Delegates at Monday's Uganda Pharmaceutical Sector Conference in Kampala heard that there are currently barely 600 qualified pharmacists in the country. According to the Pharmaceutical Society of Uganda, one pharmacist serves an average of 100,000 people- way below the World Health Organisation recommendation of one for every 2,000. To redress the.
Reddy s ANDA is approved by the United States Food& Drug Administration. The Allegra-D 12 Hour brand has U.S. sales of approximately $49.8 million for the latest 52 weeks ending October 6, 2014 for Total US Multi Outlet according to IRI. Reddy s Laboratories Ltd. is an integrated global pharmaceutical company, committed to providing afford
Tokyo, Nov 20, 2014 JCI Pharmaceutical Co., Ltd. has announced approval by the US FDA for its MN colloid iodine, a formulation utilizing a world-first technology for converting iodine into a colloidal state to make it absorbable into the body at a large doses. The new formulation converts iodine into a colloid state and further processes it to ma
Purdue Pharma L.P. announced that the U.S. Food and Drug Administration approved Hysingla ER extended-release tablets CII, a once-daily, single-entity medication formulated using Purdue's proprietary extended-release solid oral platform, RESISTEC?. It is the first and only hydrocodone product to be recognized by the FDA as having abuse-deterren
Axxess Pharma Inc., a specialty pharmaceutical and nutritional supplements company, through its wholly owned subsidiary, AllStar Health Brands Inc., is pleased to announce they have now received Health Canada approval to sell their high potency Omega-3 fish oil supplement throughout Canada. The Omega-3 fish oil will be sold under the globally recog
Parker Waichman LLP, a national law firm representing patients injured by drugs and medical devices comments on a recall of Mayhem dietary supplements, produced by Chaotic Labz of Atkins, Arkansas. The recall was prompted after a U.S. Food and Drug Administration laboratory analysis revealed the supplement contained undeclared prescription drugs,..
Forward-looking statements may also be made in the Company's other reports filed with or furnished to the SEC and in other documents. PuraMed BioScience , Inc. was incorporated in Minnesota on May 9, 2006, as a wholly-owned subsidiary of Wind Energy America, Inc. for the purpose of engaging in the business of developing and marketing non-prescrip